Summit Creek Advisors LLC Purchases Shares of 219,312 Vericel Corporation $VCEL
Summit Creek Advisors LLC has acquired 219,312 shares of Vericel Corporation (NASDAQ:VCEL), valued at approximately $9.76 million, making it their second-largest holding. Other institutions like BlackRock and TimesSquare Capital also initiated new positions, while State Street, GW&K, and Goldman Sachs increased their stakes. Vericel recently reported strong quarterly earnings, exceeding analyst estimates with $77.46 million in revenue and $0.04 EPS.
TimesSquare Capital Management LLC Invests $24.46 Million in Vericel Corporation $VCEL
TimesSquare Capital Management LLC has invested $24.46 million in Vericel Corporation (VCEL), acquiring 549,846 shares. Other institutional investors have also increased their holdings, while company insiders sold shares. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $58.40, following strong quarterly earnings that exceeded expectations.
Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Vericel Corporation (NASDAQ:VCEL) during the first quarter, purchasing an additional 180,761 shares to own a total of 1.10 million shares valued at $35.3 million. This investment follows a strong financial performance by Vericel, which reported quarterly revenue of $77.46 million, a 22.5% year-over-year increase, and an EPS of $0.04, surpassing analyst expectations. Despite insider selling of 52,232 shares worth approximately $2.3 million in the past three months, analysts maintain a "Moderate Buy" rating for VCEL, with an average price target of $58.40.
Vericel Corp Director Kevin McLaughlin Executes Stock Options and Sells Shares Under 10b5-1 Plan
Vericel Corp (NASDAQ:VCEL) Director Kevin F. McLaughlin exercised stock options for 7,000 shares at $13.05 per share and subsequently sold those shares at $44.53 per share on August 12, 2026. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted in May 2025. Following the sale, McLaughlin directly holds 18,300 shares of common stock and 7,000 stock options.
Vericel (VCEL) director exercises 7,000 options and sells 7,000 shares
Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options at $13.05 per share and subsequently sold 7,000 common shares at $44.53 per share on August 12, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted in May 2025. The options originated from a 2018 grant for 17,500 shares that vested monthly.
Soleus Capital group (VCEL) discloses 2.8% Vericel ownership under 5% level
Soleus Capital Master Fund, L.P. and associated entities have reported a beneficial ownership of 2.8% in Vericel Corp (VCEL) common stock, totaling 1,458,882 shares. This updated disclosure, filed on an amended Schedule 13G, places their ownership below the 5% threshold, indicating passive investment. All voting and dispositive authority over these shares is shared among the reporting persons.
Kevin McLaughlin (VCEL) to sell 7,000 shares after stock option exercise
Kevin McLaughlin, an insider at Vericel Corp (VCEL), has filed a notice of proposed sale for 7,000 shares of common stock. This sale is scheduled for on or after August 12, 2026, and is associated with a stock option exercise. McLaughlin previously sold 7,000 shares on May 13, 2026, for $229,777.45, and the current proposed sale has an aggregate market value of $308,770.00.
Vericel Corporation $VCEL Shares Sold by Kopp Family Office LLC
Kopp Family Office LLC significantly reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 68.7% in the second quarter, selling 112,302 shares and retaining 51,053 shares valued at approximately $2.27 million. Despite this, Vericel reported strong Q2 earnings, exceeding expectations with $0.04 EPS and $77.46 million in revenue, a 22.5% year-over-year increase. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $58.40.
3 Major Earnings Winners You May Have Missed
This article highlights three companies, Vericel (VCEL), Xenia Hotels & Resorts (XHR), and International Paper (IP), that posted notable earnings results but may have been overlooked during earnings season. Vericel, a biotech firm, showed strong financials and raised its revenue guidance, while Xenia Hotels & Resorts, a REIT, improved key metrics despite a net loss from an impairment charge. International Paper, undergoing transformation, demonstrated operational improvements and box volume growth despite missing revenue estimates.
Vericel Corp (VCEL) Stock News Today
This article provides current stock information for Vericel Corp (VCEL), including its latest stock price, market cap, and P/E TTM. It notes that more news and updates for VCEL stock will be available soon. The page serves as a hub for news, analysis, financials, and other investment-related data for Vericel Corp.
Vericel Corp (VCEL) COO exercises options, sells 10,000 shares
Vericel Corp's Chief Operating Officer, Michael Halpin, exercised stock options to acquire 10,000 shares at $16.66 per share and simultaneously sold these 10,000 shares at $46.84 per share on August 3, 2026. This transaction, executed under a Rule 10b5-1 trading plan established on December 2, 2025, resulted in an approximate pre-tax spread of $302,000. After the transaction, Halpin still holds 26,250 stock options and 16,394 common shares directly.
Q3 2025 Vericel Corp Earnings Call Transcript
Vericel Corp (FRA:ATQP) reported record Q3 2025 total revenue of $67.5 million, exceeding guidance, primarily driven by a 25% increase in Macy revenue and strong biopsy growth. The company achieved a GAAP net income over $5 million and an adjusted EBITDA margin of 25%, alongside record operating cash flow of over $22 million. Vericel is also preparing to initiate a phase 3 Macy ankle clinical study, indicating future growth opportunities despite anticipated increased operating expenses and caution regarding 2026 guidance.
Form 144 Vericel Corp For: 3 August By Investing.com
This article from Investing.com announces the filing of Form 144 by Vericel Corp on August 3rd. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates plan to sell shares. The brief note provides the date of the filing and mentions Vericel Corp's stock symbol VCEL.
Form 144 Vericel Corp For: 3 August By Investing.com
This article from Investing.com reports the filing of Form 144 for Vericel Corp on August 3rd. Form 144 is typically filed with the SEC when an insider intends to sell restricted or controlled securities. The article provides only the title and date of the filing, without further details about the transaction.
Vericel (VCEL) insider Michael Halpin files to sell 10,000 shares
Vericel Corporation insider Michael Halpin has filed to sell 10,000 shares of common stock, valued at $459,800.00, on August 3, 2026, through Fidelity Brokerage Services LLC. These shares are related to a stock option exercise on the same date. Halpin also previously sold 10,000 shares on June 18, 2026, for proceeds of $402,401.05.
Vericel Corp (VCEL) officer exercises options and sells 4,500 shares
Jonathan Siegal, Principal Accounting Officer at Vericel Corp (VCEL), exercised stock options for 4,500 shares and subsequently sold all 4,500 shares at $48.90 per share on July 30, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025. This transaction involved exercise prices of $34.90 and $29.82 per share, resulting in approximate gross sale proceeds of $220K and a pre-tax spread of $78K.
VERICEL CORP : LEERINK PARTNERS RAISES TARGET PRICE TO $59.00 FROM $46.00
LEERINK PARTNERS has increased its target price for VERICEL CORP (VCEL.O) to $59.00, up from the previous target of $46.00. This update reflects a significant change in the analyst's valuation of the company. The information was released by Reuters.
Earnings call transcript: Vericel tops Q2 2026 estimates, lifts outlook
Vericel Corporation (VCEL) reported second-quarter 2026 earnings and revenue that exceeded Wall Street estimates, driven by strong performance in its MACI cartilage repair and burn care businesses. The company raised its full-year 2026 revenue guidance to $330 million-$340 million and announced a $200 million share repurchase program, its first ever. Management highlighted continued momentum, strategic investments, and robust cash generation, positioning Vericel for sustained growth towards its long-term revenue and profitability targets.
Vericel (VCEL) insider files to sell 4,500 shares after option exercise
Vericel (VCEL) insider Jonathan Siegal filed a Form 144 to sell 4,500 shares of common stock, valued at an aggregate of $220,050.00, following a stock option exercise on July 30, 2026. The sale will be executed through Fidelity Brokerage Services LLC. This filing follows several other share sales by Siegal in the preceding three months, totaling over 7,500 shares.
Vericel Corp Ord earnings beat by $0.07, revenue topped estimates
Vericel Corp Ord (NASDAQ: VCEL) reported second-quarter earnings per share of $0.04, exceeding analyst estimates by $0.07. The company's revenue of $77.45 million also surpassed the consensus estimate of $72.7 million. Vericel Corp Ord's stock has shown strong performance, rising over 31% in the last three months and over 33% in the last year, reflecting a "great performance" in its financial health according to InvestingPro.
Vericel Corp 2Q 2026: Revenue $77.46M, EPS $0.04— 10-Q Summary
Vericel Corp reported strong second-quarter 2026 results, with revenue rising 22.5% to $77.46M and diluted EPS reaching $0.04 compared to a loss in the prior year. The growth was attributed to increased MACI and Epicel volume, MACI Arthro expansion, and the approval of the Burlington manufacturing facility for MACI production. The company is also pursuing clinical and market expansion initiatives, including the MASCOT ankle trial and UK regulatory approval for MACI.
Vericel Reports Q2 2026 Revenue Up 22% to $77.5M, Raises 2026 Guidance and Authorizes $200M Buyback
Vericel reported strong second-quarter 2026 results with total net revenue increasing 22% year-over-year to $77.5 million, driven by growth in MACI, Burn Care, and Epicel. The company raised its full-year 2026 revenue guidance to $330–$340 million and announced a $200 million share repurchase program, highlighting a strong financial position with $227 million in cash and investments.
Vericel Corp (VCEL) Q2 2026 Earnings
Vericel Corp (VCEL) reported strong Q2 2026 earnings, swinging to profitability with an EPS of $0.04 against an estimated loss of $-0.03, and revenue of $77 million, surpassing estimates of $73 million. The company also announced a $200 million share buyback, indicating confidence in sustained growth, and saw significant growth in MACI cartilage repair revenue and free cash flow.
Vericel Authorizes $200M Buyback; Q2 Revenue Rises 22%
Vericel (NASDAQ: VCEL) reported strong second-quarter 2026 financial results, with total revenue increasing 22% year-over-year to $77.5 million, driven by growth in both MACI and Burn Care segments. The company raised its full-year 2026 revenue guidance to between $330 million and $340 million and announced a $200 million share repurchase program, reflecting confidence in its sustained growth trajectory and financial performance. Net income for the quarter was $2.2 million, and Vericel ended with approximately $227 million in cash and investments and no debt.
VCEL|Vericel Corp|Price:46.560|Chg%:-0.150
This article provides a comprehensive stock analysis of Vericel Corp (VCEL) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis includes its stock score, key insights, analyst ratings (mostly "Buy" with a target price of $57.14), and a comparison with peers. The company is a biopharmaceutical firm specializing in advanced therapies for sports medicine and severe burn care markets, marketing products like MACI, Epicel, and NexoBrid.
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel Corporation (VCEL) reported Q2 earnings of $0.04 per share, significantly beating the Zacks Consensus Estimate of a $0.04 loss per share, and revenues of $77.46 million, surpassing estimates by 7.58%. The company has outperformed the S&P 500 year-to-date with a 29.5% gain, and currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
H.C. Wainwright reiterates Vericel stock rating with $70 target
H.C. Wainwright has reiterated a Buy rating on Vericel Corporation (NASDAQ:VCEL) stock, setting a price target of $70.00. The company is set to report its second-quarter 2026 results soon, with strong guidance for MACI and Burn Care revenues indicating significant year-over-year growth. Vericel's recent financial performance, including solid MACI growth and a high gross profit margin, suggests it remains undervalued.
Vericel Corporation (VCEL) Options Chain
This article provides detailed options chain data for Vericel Corporation (VCEL), including call and put options with various strike prices and expiration dates. It lists the last trade date, last price, bid, ask, volume, open interest, and implied volatility for each contract. Additionally, it displays current stock performance and related tickers.
VCEL|Vericel Corp|Price:45.320|Chg%:+0.270
Vericel Corporation is a commercial-stage biopharmaceutical company specializing in advanced therapies for sports medicine and severe burn care, marketing products like MACI, Epicel, and NexoBrid in the US. The article provides detailed company information, including its products, key executives, and financial data, noting MACI as its primary revenue source. As of Q1 2026, 583 institutions hold Vericel Corp shares, with institutional shareholding having increased significantly.
Vericel Corp (VCEL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Vericel Corp (VCEL), highlighting major institutional investors like BlackRock, State Street, and Soleus Capital Management. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for top investors. The article also lists various ETFs that include VCEL in their portfolios.
Vericel Corp (VCEL) Cash Flow
This article provides a detailed historical cash flow statement for Vericel Corp (VCEL), including operating, investing, and financing cash flows presented quarterly and annually. It features key financial metrics such as net income from continuing operations, capital expenditures, and free cash flow, along with year-over-year percentage changes. The piece also includes an FAQ section explaining different types of cash flow and their significance for investors.
Vericel Corp (VCEL) Income Statement
This article provides the quarterly and annual income statements for Vericel Corp (VCEL), offering detailed financial data ranging from total revenue to basic and diluted earnings per share. It highlights financial performance metrics and includes an FAQ section to guide users on how to interpret the income statement and key indicators for analyzing VCEL stock. The data covers multiple fiscal years and quarters, emphasizing year-over-year changes.
VCEL|Vericel Corp|Price:45.050|Chg%:+0.005
Vericel Corp (VCEL) is a commercial-stage biopharmaceutical company specializing in advanced therapies for sports medicine and severe burn care. The company's stock is currently priced at $45.050, and its fundamentals are considered healthy with high growth potential, though its valuation is seen as fairly valued within the Pharmaceuticals industry. Analysts largely rate VCEL as a "Buy" with a target price of $57.143, indicating a potential upside of 26.86%.
Vericel Corp (VCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Vericel Corp (VCEL), highlighting its current earnings forecast score of 8.50 and an average price target of $55.00 from analysts. It includes details on analyst ratings, peer comparison, expected revenue, and past and future EPS performance. The information is presented as a snapshot of the company's financial outlook based on current analyst consensus.
Vericel stock hits 52-week high at 48.41 USD
Vericel Corporation's stock has reached a 52-week high of $48.41, reflecting a significant increase of 30.58% over the past year and nearly 30% year-to-date. This milestone is supported by strong Q1 2026 financial results, where the company surpassed analyst expectations for both EPS and revenue. InvestingPro analysis suggests the stock is currently undervalued despite its strong performance, with additional insights available for deeper investor research.
Vericel stock hits 52-week high at 48.41 USD By Investing.com
Vericel Corporation (VCEL) reached a 52-week high of $48.41, giving it a market capitalization of $2.44 billion. This milestone follows the company's strong first-quarter 2026 financial results, where it surpassed analyst expectations with an EPS of -$0.12 and revenue of $68.4 million. The positive performance and outlook have garnered attention from investors and market analysts.
Vericel stock hits 52-week high at 48.41 USD By Investing.com
Vericel Corporation's stock (VCEL) has reached a 52-week high of $48.41, marking a significant milestone and reflecting strong investor confidence with a market capitalization of $2.44 billion. This performance follows a substantial 30.58% increase over the past year and nearly 30% year-to-date returns. The company also reported robust Q1 2026 financial results, surpassing analyst expectations with an EPS of -$0.12 and revenue of $68.4 million.
VCEL Maintained by Truist Securities -- Price Target Raised to $54.00
Truist Securities has reiterated its 'Buy' rating for Vericel (VCEL) and increased its price target to $54.00 from $42.00, suggesting a potential 28.57% upside from its current price. GuruFocus indicates VCEL is undervalued by 12.9% with a GF Value of $55.02 and a strong GF Score of 83/100, though insider selling has been noted recently. Vericel is a biopharmaceutical company focusing on sports medicine and severe burn care.
Vericel stock hits 52-week high at 48.41 USD By Investing.com
Vericel Corporation's stock reached a 52-week high of $48.41, with a market capitalization of $2.44 billion, showing a 30.58% increase over the past year. InvestingPro analysis suggests the stock is undervalued, and recent financial results for Q1 2026 surpassed analyst expectations with an EPS of -$0.12 and revenue of $68.4 million. This strong performance highlights investor confidence and positive company trajectory.
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
Vericel Corporation announced it will report its second-quarter 2026 financial results on Thursday, July 30, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and business highlights. Vericel specializes in advanced therapies for sports medicine and severe burn care markets, marketing products like MACI, Epicel, and NexoBrid.
Vericel schedules July 30 webcast for second-quarter update
Vericel (NASDAQ: VCEL) announced it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, with a conference call and live webcast scheduled for 8:30 a.m. ET to review the results and business highlights. The company, a leader in advanced therapies for sports medicine and severe burn care, has seen modest historical reactions to earnings date notices, with recent net insider selling noted. The webcast replay will be available until July 30, 2027.
Is Vericel (NASDAQ:VCEL) Emerging As A Small-Cap Healthcare Story?
Vericel (NASDAQ: VCEL) is gaining attention as a potential small-cap healthcare success story due to its specialized cell therapy products. The company focuses on regenerative medicine, cartilage repair, and burn care. Its manufacturing quality and commercial execution are key factors attracting interest in the healthcare sector.
Vericel stock hits 52-week high at 47.15 USD
Vericel Corporation's stock reached a new 52-week high of $47.15, marking a 30% year-to-date return and a 19.16% increase over the last 12 months. This achievement follows strong Q1 2026 financial results, where the company surpassed EPS and revenue expectations. InvestingPro analysis suggests the stock may still be undervalued despite its recent gains.
Vericel CMO Jonathan Hopper sells $450,000 in company stock By Investing.com
Vericel's Chief Medical Officer, Jonathan Hopper, sold 10,000 shares of company stock for $450,000 but also acquired 10,000 shares through option exercises for $298,200. These transactions occurred while Vericel's stock traded near its 52-week high, with an InvestingPro analysis suggesting it remains undervalued. The company recently reported strong Q1 2026 financial results, exceeding both earnings and revenue expectations.
Form 4 Vericel Corp Ord For: 30 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Vericel Corp Ord for the period ending June 30. It provides the news without further details, alongside various market data and other news headlines. The Form 4 filing is a standard SEC document indicating changes in beneficial ownership of a company's securities by its directors, officers, or significant shareholders.
Vericel (VCEL) accounting officer sells 2,732 shares, exercises options
Vericel Corp's Principal Accounting Officer, Jonathan Siegal, exercised 2,500 stock options and sold a total of 2,732 common shares at $44.90 per share on June 26, 2026. These transactions, which generated $122,667, were pre-arranged under a Rule 10b5-1 trading plan. After these sales, Siegal holds 886 common shares and 6,500 outstanding stock options.
Vericel (VCEL) CMO exercises options, sells 10,000 shares under 10b5-1 plan
Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, executed a pre-scheduled transaction on June 26, 2026, exercising options for 10,000 shares at $29.82 each and simultaneously selling those 10,000 shares on the open market for $45.00 per share. These sales were conducted under a Rule 10b5-1 trading plan adopted in May 2025. Following the transaction, Hopper retains 75,753 direct shares and 25,000 stock options, demonstrating continued equity exposure to the company.
Vericel (VCEL) CFO executes 5,000-share Rule 10b5-1 stock sale
Vericel's CFO, Mara Joseph Anthony Jr., sold 5,000 shares of common stock at $44.75 per share on June 26, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following this transaction, he directly holds 16,009 shares. The sale, valued at $223,750, was an open-market transaction and included shares acquired through an employee stock purchase plan.
Vericel (VCEL) Chief Legal Officer sells 15,000 shares after option exercise
Vericel Corp's Chief Legal Officer, Sean C. Flynn, exercised stock options for 15,000 shares at $16.25 and subsequently sold them at an average price of $45.64 per share. These transactions, which occurred on June 26, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these sales, Flynn directly holds 1,647 shares of Vericel common stock.
Vericel CMO Jonathan Hopper sells $450,000 in company stock
Vericel Corp's Chief Medical Officer, Jonathan Hopper, sold 10,000 shares of company stock worth $450,000 but also acquired 10,000 shares through option exercises for $298,200. These transactions occurred while the stock was near its 52-week high, despite analysis suggesting it remains undervalued with potential upside. The company recently reported strong Q1 2026 results, exceeding revenue and EPS expectations.
